Incidence of different subtypes of <i>IDH1</i> mutations.

<p>Eight <i>IDH1</i> mutations were detected in 35/349 patients.</p

Survival curve of AML patients.

<p>Kaplan-Meier curve shows OS (A) in patients with IDH1non-R132 mutations and IDH1 wild type. The OS (B) in patients with non-R132 IDH1 mutations who were transplanted or non-transplanted.</p

Genetic alterations in AML patients with/without <i>IDH1</i> mutations.

<p>Genetic alterations in AML patients with/without <i>IDH1</i> mutations.</p

DNA sequencing of <i>IDH1</i> mutations.

<p>DNA sequencing chromatograms of representative heterozygous <i>IDH1</i> mutations and reference wild type <i>IDH1</i>.</p

Summary of clinical characteristics in IDH1 mutation patient.

<p>Summary of clinical characteristics in IDH1 mutation patient.</p

Patient demographics, clinical data and cytogenetic changes in AML patients with/without <i>IDH1</i> mutations.

<p>Patient demographics, clinical data and cytogenetic changes in AML patients with/without <i>IDH1</i> mutations.</p

Secondary Antifungal Prophylaxis in Hematological Malignancy Patients with Previous Invasive Fungal Disease: A Retrospective Analysis

<div><p>Background</p><p>Invasive fungal disease (IFD) causes morbidity and mortality in patients with hematological malignancy. Recurrence of IFD after chemotherapy or hematopoietic stem cell transplantation (HSCT) is associated with poor prognosis. The present study aimed to investigate the efficacy of different strategies of secondary antifungal prophylaxis (SAP) for IFD and choose an appropriate SAP regimen.</p><p>Methods</p><p>Clinical data of patients with previous IFD who underwent chemotherapy or HSCT between Jan 2008 and Jun 2013 were retrospectively reviewed and followed up to 180 days post-chemotherapy or HSCT. The clinical characteristics and diagnosis were analyzed according to the diagnostic criteria for IFD. The efficacy of different strategies for SAP and risk factors influencing the failure of SAP were evaluated.</p><p>Results</p><p>Of the 164 patients enrolled, 121 patients received SAP regimen (73.78%), and IFD recurred in 40 patients: 16.5% (20/121) in SAP group and 46.5% (20/43) in non-SAP group. In SAP group, 58 received SAP agents which were proven effective for their previous IFD, while other 63 patients received other broad-spectrum antifungal agents. There was no significant difference in the recurrence rates between these two subgroups (13.8% (8/58) vs 19.0% (12/63), P = 0.437). The IFD recurrence rates were statistically significant between patients with allogeneic HSCT and chemotherapy or autologous HSCT (25% vs 8.2%, P = 0.013). Multivariate analysis indicated that allogeneic HSCT was the independent risk factor of IFD recurrence after SAP.</p><p>Conclusions</p><p>Secondary antifungal prophylaxis is necessary to prevent IFD recurrence in patients with hematological malignancy, especially for patients in the setting of allogeneic HSCT.</p></div

Effect of oral cryotherapy on the duration of analgesic use in patients with hematological malignancies undergoing hematopoietic stem cell transplantation.

<p>SMD: standardized mean difference; CI: confidence interval.</p

Effect of oral cryotherapy on the length of hospital stay in patients with hematological malignancies undergoing hematopoietic stem cell transplantation.

<p>SMD: standardized mean difference; CI: confidence interval.</p

Effect of oral cryotherapy on the duration of oral mucositis in patients with hematological malignancies undergoing hematopoietic stem cell transplantation.

<p>SMD: standardized mean difference; CI: confidence interval.</p